Elsevier

Vaccine

Volume 29, Issue 51, 28 November 2011, Pages 9544-9550
Vaccine

Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector

https://doi.org/10.1016/j.vaccine.2011.09.097Get rights and content

Abstract

Background

Jet injectors (JIs) avoid safety drawbacks of needle–syringe (N–S) while generating similar immune responses. A new generation of disposable-syringe jet injectors (DSJIs) overcomes the cross-contamination risk of multi-use-nozzle devices used in 20th-century campaigns. In the first study in humans, the newly-US-licensed LectraJet® model M3 RA DSJI was compared to N–S.

Methods

Sixty healthy adults received one 0.5 mL intramuscular dose of the 2009–2010 seasonal, trivalent, inactivated influenza vaccine (TIV) in randomized, double-masked fashion by either DSJI (n = 30) or N–S (n = 30). Adverse reactions were monitored for 90 days after injection, and serologic responses assayed by hemagglutination inhibition (HI) at days 28 and 90.

Results

There were no related serious adverse events (SAEs), nor differing rates of unsolicited AEs between DSJI and N–S. Solicited erythema and induration occurred more often after DSJI, but were transient and well-tolerated; a trend was noted for fewer systemic reactions by DSJI. Pre-vaccination HI geometric mean titers (GMT) increased by 28 days for H1N1, H3N2, and B antigens by 13-, 14-, and 8-fold via DSJI, and by 7-, 10-, and 7-fold for N–S, respectively. No trending differences in GMT, seroconversion, or seroprotection were noted; sample sizes precluded non-inferiority assessment.

Conclusions

DSJI delivery of TIV is well-tolerated and immunogenic.

Highlights

► This report is the first in human assessment of a newly licensed jet injector LectraJet® M3 RA. ► Administration of seasonal influenza vaccine using the jet injector was well tolerated. ► The jet injector induced immune responses that were similar to needle and syringe.

Section snippets

Background

Needle-free vaccine delivery has the potential to lead to significant advances in immunization, including improved safety for the vaccinator and vaccinee, better compliance with immunization schedules, decreased fear of injection and needles, easier and speedier vaccine delivery, and reduced cost [1]. For these reasons, needle-free vaccine delivery has been supported by the World Health Organization [2], the Global Alliance for Vaccines and Immunization [3], and the Centers for Disease Control

Subjects

Healthy male and female volunteers aged 18–49 years were recruited from the Baltimore/Washington, DC area for this randomized, controlled, double-masked clinical trial. Volunteers were required to be in good health as evidenced by medical history and physical examination, if indicated. Ineligible were those who received an influenza vaccine in the 2008–2009 or 2009–2010 influenza seasons, received a live-attenuated vaccine within 30 days prior to enrollment or a killed vaccine within 14 days

Results

Sixty-five volunteers were recruited and sixty enrolled and vaccinated in February and March of 2010. Four recruits were removed from the study prior to vaccination because of the exclusion criteria of current use of antimicrobials (two recruits), a positive pregnancy test (one), and a history of a bleeding disorder (one). Another eligible volunteer changed her mind prior to being vaccinated. All thirty volunteers randomly assigned to the DSJI study arm received the vaccine by that route; all

Discussion

In this first human clinical study using LectraJet® M3 RA to administer TIV vaccination, injection using the DSJI was found to be well-tolerated and immunogenic. Higher rates of transient local reactogenicity were seen in volunteers vaccinated with the LectraJet device compared to N–S, although a trend toward fewer systemic reactions was also noted.

The traditional administration of vaccines via needles poses safety risks for patients, healthcare providers, and the community [11], [12], [13]. An

Acknowledgments

We thank the volunteers for their participation in the clinical trial, as well as the clinical, regulatory, and immunology staff at the Center for Vaccine Development, including Jane Cowan, Karimah Williams, Cara Arcidiacono, Sarah Yang, Virginia Cowan, and Kim Rincavage. We also thank William Blackwelder and Yukun Wu for randomization and statistical advice. Financial support for this research was provided by D’Antonio Consultants International, Inc., which had no technical authority over the

References (22)

  • J. Canter et al.

    An outbreak of hepatitis B associated with jet injections in a weight reduction clinic

    Arch. Intern. Med.

    (1990)
  • Cited by (31)

    • Effect of nozzle shape and applied load on jet injection efficiency

      2023, Journal of Drug Delivery Science and Technology
    • Needle-free technology for biomedical applications

      2022, Multifunctional Nanocarriers
    • Feasibility of using negative pressure for jet injection applications

      2021, Journal of Drug Delivery Science and Technology
      Citation Excerpt :

      Multiple studies [12–17] now prove that this technique is feasible for mass immunizations, which as shown by the recent pandemic, are going to be vital for forseeable future. Whilst jet injectors were originally proposed as a candidate to replace needles for standard intramuscular injections [18–22], they also clearly hold promise for fractional dose vaccine delivery [12–17], and there have been numerous studies assessing both the fundamental mechanics [23–47] and clinical success [12–17,48–51] of needle-free jet injection. The basic premise is that a high upstream pressure, created using either a spring or compressed gas mechanism, forces a jet at high-speed, vjet ~O(100 m/s), from a narrow orifice, D0 ~O(100 μm).

    View all citing articles on Scopus
    View full text